---
title: Strategies for Antibody-Drug Conjugate Bioanalysis
description: ADC bioanalysis must track the antibody, the payload and drug-to-antibody ratio changes in vivo. An overview of the two main analytical strategies.
---

[News, Events & Resources | Crystal Bio Solutions](https://www.crystalbiosolutions.com/news-and-events)

# [Strategies for Antibody-Drug Conjugate Bioanalysis](https://www.crystalbiosolutions.com/news-and-events/strategies-for-antibody-drug-conjugates-bioanalysis)

 Written by [Crystal Bio Solutions Scientific Team](https://www.crystalbiosolutions.com/news-and-events/author/crystal-bio-solutions-scientific-team) | Nov 21, 2025, 8:38:12 AM

[Antibody-drug conjugates (ADCs) combine antibody specificity with potent small-molecule payloads](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc), so their bioanalysis needs methods that capture both components and the changes that occur *in vivo*. Reliable bioanalysis underpins pharmacokinetic (PK) interpretation, safety assessment and progression into clinical development.

**Nonclinical bioanalytical studies** define ADC PK and toxicokinetics (TK) and, together with pharmacodynamic and metabolism data, help explain exposure, mechanism of action and safety margins.

## Key Considerations in ADC Bioanalysis

### 1. Heterogeneity of ADCs

ADCs are heterogeneous because of their structure and manufacturing process. Differences in drug-to-antibody ratio (DAR), drug-load distribution, linker chemistry and antibody subclass can influence efficacy and safety, and they affect which assays are needed to interpret preclinical results.

### 2. DAR Changes *In Vivo*

The average DAR usually decreases after dosing as payload is released through linker cleavage or deconjugation. Species with different drug loads can also clear at different rates, with high-DAR species often cleared faster. DAR monitoring is therefore an important part of PK evaluation.

### 3. Selection of Relevant Analytes

ADCs contain several components that change over time, so choosing analytes that represent exposure and biological effect is not straightforward.

FDA's 2024 guidance [*Clinical Pharmacology Considerations for Antibody-Drug Conjugates*](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-antibody-drug-conjugates-guidance-industry) recommends characterizing the relevant analytes, particularly in early studies, including:

- The ADC (measured as conjugated antibody and/or conjugated payload)
- Total antibody
- Unconjugated (free) payload and relevant metabolites

A broad analyte strategy supports a clearer understanding of exposure-response relationships.

## Conventional Analytical Approaches

ADC bioanalysis typically combines ligand-binding assays (LBAs) with LC-MS/MS to quantify the protein-based and small-molecule components.

**Ligand-binding assays** are widely used to measure total antibody and conjugated antibody (for example, with anti-payload capture or detection). They need high-quality reagents, which can be difficult to obtain early in development, and they can be affected by anti-drug antibodies.

**LC-MS/MS** is the standard technology for free payload, offering high sensitivity and specificity.

## Hybrid LC-MS/MS

Hybrid (affinity capture) LC-MS/MS methods have become widely used in ADC bioanalysis. The ADC is captured from the sample, digested, and quantified through signature peptides of the antibody or through payload released from the linker. This reduces dependence on molecule-specific reagents and allows several ADC-related analytes to be measured from the same sample.

Advantages during early development include:

- Applicability to many humanized or fully human IgG1 and IgG4 backbones
- Shorter method development timelines
- Less reliance on specialized anti-idiotype reagents
- Coverage of total antibody, conjugated payload and released payload

LC-MS/MS-based approaches are increasingly used alongside LBAs because of their specificity and wide dynamic range. Both are accepted for regulated studies when validated according to ICH M10, and the choice depends on the molecule and the question being asked.

## A General-Purpose Nonclinical Method for ADC Bioanalysis

Most ADCs in development use humanized or fully human IgG1 (and some IgG4) antibodies, which makes a general-purpose assay strategy practical for nonclinical studies.

Crystal Bio Solutions has developed a general LC-MS/MS approach in its Pleasanton, California bioanalysis laboratory that includes:

- **Antibody quantification** through signature peptides from the human IgG1 or IgG4 constant region, which can be distinguished from endogenous IgG in animal matrices
- **Conjugated payload quantification** through enzymatic cleavage of peptide-based linkers to release the payload, enabling average DAR to be followed *in vivo*

Combined with LC-MS/MS measurement of free payload, this strategy supports measurement of:

- Total antibody
- Conjugated payload
- Free payload

These data support PK characterization, DAR monitoring, and nonclinical pharmacology and toxicology evaluation.

To see method performance, read our case study [A Generic LC-MS/MS Solution for ADC PK Bioanalysis](https://www.crystalbiosolutions.com/news-and-events/a-generic-lc-ms/ms-solution-for-adc-pk-bioanalysis).

For an overview of our total antibody, conjugated payload and free payload methods, see [PK assays for biologics and ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis).

[View full post](https://www.crystalbiosolutions.com/news-and-events/strategies-for-antibody-drug-conjugates-bioanalysis)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Crystal Bio Solutions Scientific Team"
  },
  "dateModified" : "2026-11-22T00:27:28.908Z",
  "datePublished" : "2025-11-21T08:38:12Z",
  "headline" : "Strategies for Antibody-Drug Conjugate Bioanalysis",
  "image" : {
    "@type" : "ImageObject",
    "height" : 300,
    "url" : "https://cbs.crystalpharmatech.com/hubfs/Thumbnail-Crystal-Bio-Solutions.png",
    "width" : 600
  },
  "mainEntityOfPage" : "https://www.crystalbiosolutions.com/news-and-events/strategies-for-antibody-drug-conjugates-bioanalysis",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60.0,
      "url" : "https://146565877.fs1.hubspotusercontent-eu1.net/hubfs/146565877/CBS%20VI%20v1/Crystal%20Bio%20Solution-%E7%99%BD%E5%BA%95%E5%9B%BE%E7%89%87.jpg",
      "width" : 196.30608
    },
    "name" : "News, Events & Resources"
  }
}
```